TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05956587: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Car

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 121 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,365,200

Rescue Site Savings

+$7,484,400

Unlock Full NCT05956587 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05956587 Rescue Dossier →